sector medic suppli devic
messag report strong fiscal result morn solid top
line momentum organ growth drove earn upsid top-lin beat
broad base heart failur segment fall short consensu
view perform encourag littl shift think
outlook next month estim rel unchang
essenti line current street consensu walk model
chang beyond
decreas adjust ep estim yoy
in-lin midpoint manag guidanc rang top
line model call total revenu organ
prior estim primarili due reduc fx tailwind cvg forecast
modest declin cardiac rhythm heart failur cc off-set
strength coronari structur heart cc aortic peripher
vascular cc mitg expect surgic solut revenu come
cc respiratori gastrointestin renal ad
organ sale meanwhil expect rtg growth boost
strength brain therapi cc specialti therapi
cc pain therapi cc partial off-set slower growth spine
cc final increas diabet estim
cc back quarter strong perform evid
benefit increas attach rate cgm system sensor-
augment pump becom bigger part portfolio
longer term continu see grower
top bottom line respect outlook slightli large-cap med-tech
group averag roughli share trade modest discount
peer price-to-earnings vs ev/ebitda vs basi view
valuat fair current level maintain neutral rate
page analyst certif import disclosur
wake covidien merger emerg largest med-tech
compani world boast lead franchis across wide varieti end market
ceo omar ishrak activ work translat unmatch scale competit
advantag healthcar landscap shift fee-for-valu model view
uniqu well posit regard expect process play
slowli meantim see limit upsid potenti near-term street expect
without stock current valuat appear fair view
re-envis mean centuri devic compani pursu
goal deliv econom valu uniqu combin technolog
servic go far beyond tradit purview med-tech much success
initi profit remain
seen howev think concept valu healthcar stay
someth compani space need think go forward
servic push sure make wave see manag abil deliv
margin goal real key stori next month view
manag goal deliv ebita expans ambiti
requir greater annual underli margin improv year medtron
project even tailwind covidien synergi wind
model conserv call gain
share current trade ntm ep estim
ntm ebitda repres discount large-cap med-tech group averag
respect view valuat appropri given medtron
project growth profil top bottom line
respect mani higher growth peer better opportun
elsewher group view assign medtron neutral rate
upsid risk rate includ revenu growth exce forecast better-
than-expect execut margin target faster expect shift fee-
for-valu healthcar paradigm benefit compani superior scale play
medtron strength prove disrupt competitor
downsid risk rate includ clinic setback weaker-than-expect
adopt new product caus revenu fall short street estim better-
than-expect share gain competitor failur execut margin expans
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
million usd
compani report guggenheim secur llc estim
page analyst certif import disclosur
